{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:39:55Z","timestamp":1781840395115,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005440","name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review","doi-asserted-by":"publisher","award":["P30 CA77598"],"award-info":[{"award-number":["P30 CA77598"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT) is associated with systemic inflammation and endothelial dysfunction, increasing risk for thromboembolic events (TEE). In 145 adult recipients who developed cGVHD after a matched sibling or umbilical cord blood donor HCT from 2010 to 2018, 32(22%) developed at least 1 TEE event, and 14(10%) developed 2 TEE events. The 5-year cumulative incidence of TEE was 22% (95% CI, 15\u201329%) with a median time from cGVHD to TEE of 234 days (range, 12\u20132050). Median time to the development of LE DVT or PE was 107 (range, 12\u20131925) compared to 450 days (range, 158\u20131300) for UE DVT. Cumulative incidence of TEE was 9% (95% CI, 0\u201320%), 17% (95% CI, 9\u201325%), and 38% (95% CI, 22\u201355%) in those with mild, moderate, and severe GVHD, respectively. Higher risk for TEE was associated with cGVHD severity (hazard ratio [HR] 4.9, [95% CI, 1.1\u201322.0]; <jats:italic>p<\/jats:italic>\u2009=\u20090.03), non-O-donor to recipient ABO match compared to O-donor to O-recipient match (HR 2.7, [95% CI, 1.0\u20137.5]; <jats:italic>p<\/jats:italic>\u2009=\u20090.053), and personal history of coronary artery disease (HR 2.4, [95% CI, 1.1\u20135.3]; <jats:italic>p<\/jats:italic>\u2009=\u20090.03). TEE was not associated with 2-year non-relapse mortality or 5-year overall survival.<\/jats:p>","DOI":"10.1038\/s41408-021-00488-2","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T09:02:53Z","timestamp":1621328573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-9655","authenticated-orcid":false,"given":"Najla","family":"El Jurdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Elhusseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"DeFor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3439-4362","authenticated-orcid":false,"given":"Grigori","family":"Okoev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rogosheske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-6436","authenticated-orcid":false,"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-3799","authenticated-orcid":false,"given":"Claudio G.","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0782-1170","authenticated-orcid":false,"given":"Fiona","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shernan G.","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-8007","authenticated-orcid":false,"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Gangaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1732-6694","authenticated-orcid":false,"given":"Joseph","family":"Maakaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-0852","authenticated-orcid":false,"given":"Margaret L.","family":"MacMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica D.","family":"Warlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Vercellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"488_CR1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1172\/JCI90593","volume":"127","author":"KPA MacDonald","year":"2017","unstructured":"MacDonald, K. P. A., Blazar, B. R. & Hill, G. R. Cytokine mediators of chronic graft-versus-host disease. J. Clin. Invest. 127, 2452\u20132463 (2017).","journal-title":"J. Clin. Invest."},{"key":"488_CR2","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/bloodadvances.2019000222","volume":"3","author":"M Furukawa","year":"2019","unstructured":"Furukawa, M. et al. A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD. Blood Adv. 3, 2128\u20132143 (2019).","journal-title":"Blood Adv."},{"key":"488_CR3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood-2011-02-334821","volume":"118","author":"T Luft","year":"2011","unstructured":"Luft, T. et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 118, 1685\u20131692 (2011).","journal-title":"Blood"},{"key":"488_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbmt.2012.09.018","volume":"19","author":"S Dietrich","year":"2013","unstructured":"Dietrich, S. et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol. Blood Marrow Transplant. 19, 22\u201327 (2013).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"488_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0140-6736(11)61306-8","volume":"379","author":"SB Z\u00f6ller","year":"2012","unstructured":"Z\u00f6ller, S. B. et al. Articles Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 379, 244\u2013293 (2012).","journal-title":"Lancet"},{"key":"488_CR6","doi-asserted-by":"publisher","first-page":"33022","DOI":"10.1074\/jbc.M705824200","volume":"282","author":"LO Mosnier","year":"2007","unstructured":"Mosnier, L. O., Yang, X. V. & Griffin, J. H. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J. Biol. Chem. 282, 33022\u201333033 (2007).","journal-title":"J. Biol. Chem."},{"key":"488_CR7","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","volume":"125","author":"JH Griffin","year":"2015","unstructured":"Griffin, J. H., Zlokovic, B. V. & Mosnier, L. O. Activated protein C: biased for translation. Blood 125, 2898\u20132907 (2015).","journal-title":"Blood"},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-016-0009-6","volume":"8","author":"S Ranjan","year":"2017","unstructured":"Ranjan, S. et al. Activated protein C protects from GvHD via PAR2\/PAR3 signalling in regulatory T-cells. Nat. Commun. 8, 1\u201316 (2017).","journal-title":"Nat. Commun."},{"key":"488_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/bmt.2014.208","volume":"50","author":"T Ikezoe","year":"2015","unstructured":"Ikezoe, T., Yang, J., Nishioka, C. & Yokoyama, A. Thrombomodulin alleviates murine GVHD in association with an increase in the proportion of regulatory T cells in the spleen. Bone Marrow Transplant. 50, 113\u2013120 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"488_CR10","doi-asserted-by":"publisher","unstructured":"Gerber, D. E. et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. (2008). https:\/\/doi.org\/10.1182\/blood-2007-10-117051.","DOI":"10.1182\/blood-2007-10-117051"},{"key":"488_CR11","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/j.1538-7836.2008.03077.x","volume":"6","author":"A Gonsalves","year":"2008","unstructured":"Gonsalves, A. et al. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J. Thromb. Haemost. 6, 1468\u20131473 (2008).","journal-title":"J. Thromb. Haemost."},{"key":"488_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2012.069559","volume":"98","author":"J Labrador","year":"2013","unstructured":"Labrador, J. et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica 98, 437\u2013443 (2013).","journal-title":"Haematologica"},{"key":"488_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3324\/haematol.2017.164012","volume":"102","author":"N Kekre","year":"2017","unstructured":"Kekre, N. et al. Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 102, 1185\u20131191 (2017).","journal-title":"Haematologica"},{"key":"488_CR14","first-page":"389","volume":"21","author":"MH Jagasia","year":"2016","unstructured":"Jagasia, M. H. et al. Nih GVHD 2014. 21, 389\u2013401 (2016).","journal-title":"Nih GVHD 2014."},{"key":"488_CR15","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand, P. et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 123, 3664\u20133671 (2014).","journal-title":"Blood"},{"key":"488_CR16","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror, M. L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106, 2912\u20132919 (2005).","journal-title":"Blood"},{"key":"488_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","volume":"16","author":"DY Lin","year":"1997","unstructured":"Lin, D. Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat. Med. 16, 901\u2013910 (1997).","journal-title":"Stat. Med."},{"key":"488_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"488_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","volume":"68","author":"RL Prentice","year":"1981","unstructured":"Prentice, R. L., Williams, B. J. & Peterson, A. V. On the regression analysis of multivariate failure time data. Biometrika 68, 373\u2013379 (1981).","journal-title":"Biometrika"},{"key":"488_CR20","doi-asserted-by":"crossref","unstructured":"Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. Ser. B 34, (1972).","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"488_CR21","doi-asserted-by":"publisher","unstructured":"Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in observational studies for causal effects. Matched Sampl. Causal Eff. 170\u2013184 (2006). https:\/\/doi.org\/10.1017\/CBO9780511810725.016.","DOI":"10.1017\/CBO9780511810725.016"},{"key":"488_CR22","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(02)08907-9","volume":"359","author":"BC Biedermann","year":"2002","unstructured":"Biedermann, B. C. et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359, 2078\u20132083 (2002).","journal-title":"Lancet"},{"key":"488_CR23","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.bbmt.2014.05.002","volume":"20","author":"A Bouazzaoui","year":"2014","unstructured":"Bouazzaoui, A. et al. Endothelial dysfunction and altered mechanical and structural properties of resistance arteries in a murine model of graft-versus-host disease. Biol. Blood Marrow Transplant. 20, 1493\u20131500 (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"488_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.bmt.1700767","volume":"19","author":"C Salat","year":"1997","unstructured":"Salat, C. et al. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant 19, 909\u2013914 (1997).","journal-title":"Bone Marrow Transplant"},{"key":"488_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","volume":"130","author":"NJ Gloude","year":"2017","unstructured":"Gloude, N. J. et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood 130, 1259\u20131266 (2017).","journal-title":"Blood"},{"key":"488_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/mpo.10145","volume":"40","author":"G Luzzatto","year":"2003","unstructured":"Luzzatto, G. et al. Markers of endothelial function in pediatric stem cell transplantation for acute leukemia. Med. Pediatr. Oncol. 40, 9\u201312 (2003).","journal-title":"Med. Pediatr. Oncol."},{"key":"488_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1538-7836.2007.02818.x","volume":"6","author":"O Wu","year":"2008","unstructured":"Wu, O., Bayoumi, N., Vickers, M. A. & Clark, P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J. Thrombosis Haemost. 6, 62\u201369 (2008).","journal-title":"J. Thrombosis Haemost."},{"key":"488_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.thromres.2008.02.003","volume":"123","author":"TR Ketch","year":"2008","unstructured":"Ketch, T. R. et al. ABO blood types: Influence on infarct size, procedural characteristics and prognosis. Thromb. Res. 123, 200\u2013205 (2008).","journal-title":"Thromb. Res."},{"key":"488_CR29","doi-asserted-by":"publisher","unstructured":"Wang, G. et al. Association between ABO blood group and venous thrombosis related to the peripherally inserted central catheters in cancer patients. J. Vasc. Access (2020). https:\/\/doi.org\/10.1177\/1129729820954721.","DOI":"10.1177\/1129729820954721"},{"key":"488_CR30","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/j.1537-2995.2006.00975.x","volume":"46","author":"PV Jenkins","year":"2006","unstructured":"Jenkins, P. V. & O\u2019Donnell, J. S. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 46, 1836\u20131844 (2006).","journal-title":"Transfusion"},{"key":"488_CR31","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","volume":"125","author":"PJ Lenting","year":"2015","unstructured":"Lenting, P. J., Christophe, O. D. & Denis, C. V. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 125, 2019\u20132028 (2015).","journal-title":"Blood"},{"key":"488_CR32","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1161\/ATVBAHA.120.314575","volume":"40","author":"LA Holle","year":"2020","unstructured":"Holle, L. A., Monroe, D. M. & Wolberg, A. S. VWF (von Willebrand Factor) is not required for red blood cell retention in clots in mice. Arterioscler. Thromb. Vasc. Biol. 40, 1952\u20131954 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"488_CR33","doi-asserted-by":"publisher","unstructured":"Ward, S., O\u2019Sullivan, J. & O\u2019Donnell, J. S. The relationship between ABO blood group, von Willebrand factor and primary hemostasis. Blood (2020). https:\/\/doi.org\/10.1182\/blood.2020005843.","DOI":"10.1182\/blood.2020005843"},{"key":"488_CR34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/ATVBAHA.116.308524","volume":"37","author":"TM Brophy","year":"2017","unstructured":"Brophy, T. M. et al. Plasmin cleaves von willebrand factor at K1491-R1492 in the A1-A2 linker region in a shear- and glycan-dependent manner in vitro. Arterioscler. Thromb. Vasc. Biol. 37, 845\u2013855 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"488_CR35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/jth.13294","volume":"14","author":"S Alb\u00e1nez","year":"2016","unstructured":"Alb\u00e1nez, S. et al. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J. Thromb. Haemost. 14, 953\u2013963 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"488_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1172\/JCI8071","volume":"105","author":"Y Lin","year":"2000","unstructured":"Lin, Y., Weisdorf, D. J., Solovey, A. & Hebbel, R. P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105, 71\u201377 (2000).","journal-title":"J. Clin. Invest."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00488-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:45:15Z","timestamp":1669909515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00488-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00488-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.W.\u2014research support from Incyte. B.R.B.\u2014founder of Tmunity Therapeutics, advisory board member for Kadmon Pharmaceuticals, Magenta Therapeutics, and BlueRock Therapeutics and receives research funding from BlueRock Therapeutics. S.G.H.\u2014consultant for Incyte. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"96"}}